JP6708544B2 - 新規抗体フレームワーク - Google Patents

新規抗体フレームワーク Download PDF

Info

Publication number
JP6708544B2
JP6708544B2 JP2016522319A JP2016522319A JP6708544B2 JP 6708544 B2 JP6708544 B2 JP 6708544B2 JP 2016522319 A JP2016522319 A JP 2016522319A JP 2016522319 A JP2016522319 A JP 2016522319A JP 6708544 B2 JP6708544 B2 JP 6708544B2
Authority
JP
Japan
Prior art keywords
antigen
sequence
framework
human
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016522319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523537A5 (enExample
JP2016523537A (ja
Inventor
マイアー ゼバスティアン
マイアー ゼバスティアン
ウレヒ ダービト
ウレヒ ダービト
Original Assignee
ヌマブ セラピューティクス アクチェンゲゼルシャフト
ヌマブ セラピューティクス アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌマブ セラピューティクス アクチェンゲゼルシャフト, ヌマブ セラピューティクス アクチェンゲゼルシャフト filed Critical ヌマブ セラピューティクス アクチェンゲゼルシャフト
Publication of JP2016523537A publication Critical patent/JP2016523537A/ja
Publication of JP2016523537A5 publication Critical patent/JP2016523537A5/ja
Application granted granted Critical
Publication of JP6708544B2 publication Critical patent/JP6708544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2016522319A 2013-06-26 2014-06-26 新規抗体フレームワーク Active JP6708544B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003264.2 2013-06-26
EP13003264 2013-06-26
PCT/EP2014/001730 WO2014206561A1 (en) 2013-06-26 2014-06-26 Novel antibody frameworks

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019111990A Division JP2019201643A (ja) 2013-06-26 2019-06-17 新規抗体フレームワーク

Publications (3)

Publication Number Publication Date
JP2016523537A JP2016523537A (ja) 2016-08-12
JP2016523537A5 JP2016523537A5 (enExample) 2018-01-18
JP6708544B2 true JP6708544B2 (ja) 2020-06-10

Family

ID=48699516

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016522319A Active JP6708544B2 (ja) 2013-06-26 2014-06-26 新規抗体フレームワーク
JP2019111990A Withdrawn JP2019201643A (ja) 2013-06-26 2019-06-17 新規抗体フレームワーク
JP2021169020A Pending JP2022028659A (ja) 2013-06-26 2021-10-14 新規抗体フレームワーク
JP2023199881A Pending JP2024026176A (ja) 2013-06-26 2023-11-27 新規抗体フレームワーク

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019111990A Withdrawn JP2019201643A (ja) 2013-06-26 2019-06-17 新規抗体フレームワーク
JP2021169020A Pending JP2022028659A (ja) 2013-06-26 2021-10-14 新規抗体フレームワーク
JP2023199881A Pending JP2024026176A (ja) 2013-06-26 2023-11-27 新規抗体フレームワーク

Country Status (12)

Country Link
US (3) US10174102B2 (enExample)
EP (1) EP3013864A1 (enExample)
JP (4) JP6708544B2 (enExample)
KR (4) KR20220029763A (enExample)
CN (2) CN113943366B (enExample)
AU (2) AU2014301629B2 (enExample)
CA (1) CA2914829A1 (enExample)
HK (1) HK1218549A1 (enExample)
IL (3) IL243311B (enExample)
NZ (1) NZ714320A (enExample)
SG (2) SG11201509899PA (enExample)
WO (1) WO2014206561A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914829A1 (en) 2013-06-26 2014-12-31 Numab Ag Novel antibody frameworks
IL293435A (en) 2015-06-15 2022-07-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
BR112018067698A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag células modificadas para imunoterapia
ES2836349T3 (es) 2016-03-17 2021-06-24 Tillotts Pharma Ag Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos
CA3011502A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnf.alpha.-antibodies and functional fragments thereof
WO2017158079A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnfalpha-antibodies and functional fragments thereof
US10774140B2 (en) 2016-03-17 2020-09-15 Numab Therapeutics AG Anti-TNFα-antibodies and functional fragments thereof
RS61412B1 (sr) 2016-03-17 2021-03-31 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
US12098203B2 (en) 2017-06-05 2024-09-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
AU2018280679B2 (en) 2017-06-05 2025-04-24 Numab Therapeutics AG Novel anti-HSA antibodies
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
KR102651965B1 (ko) 2017-06-05 2024-03-28 누맙 세러퓨틱스 아게 신규 항 cd3 항체
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
CN116199785A (zh) * 2017-06-25 2023-06-02 西雅图免疫公司 多特异性抗体及其制备和使用方法
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP3917954A1 (en) 2019-01-31 2021-12-08 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
WO2022147338A1 (en) * 2020-12-30 2022-07-07 Ascendo Biotechnology, Inc. Monoclonal antibody against human mac-1 and uses thereof
CN116848136A (zh) 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
CA3213283A1 (en) 2021-03-11 2022-09-15 IgGenix, Inc. Methods and systems for predicting allergic response
AR128065A1 (es) 2021-12-22 2024-03-20 Cdr Life Ag Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
CN120882418A (zh) * 2022-11-04 2025-10-31 MiNK治疗公司 B细胞成熟抗原(bcma)嵌合抗原受体不变自然杀伤t细胞及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
EP1651659A4 (en) 2003-08-07 2008-09-17 Epitomics Inc METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
CN101868477A (zh) 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
MX2009013328A (es) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
JP5956752B2 (ja) * 2008-06-25 2016-07-27 エスバテック − ア ノバルティス カンパニー エルエルシー Ｖｅｇｆを阻害する安定かつ可溶性の抗体
KR101882352B1 (ko) 2008-06-25 2018-07-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
ES2861592T3 (es) * 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
WO2010144780A1 (en) 2009-06-12 2010-12-16 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
EP2563812A4 (en) * 2010-04-30 2016-01-13 Alexion Pharma Inc ANTIBODIES WITH REDUCED IMMUNOGENITY IN HUMANS
WO2012163519A1 (en) * 2011-05-27 2012-12-06 Dutalys Antibodies with improved folding stability
CA2914829A1 (en) 2013-06-26 2014-12-31 Numab Ag Novel antibody frameworks
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations

Also Published As

Publication number Publication date
CN113943366A (zh) 2022-01-18
JP2019201643A (ja) 2019-11-28
CN105579472A (zh) 2016-05-11
CN105579472B (zh) 2021-10-22
HK1218549A1 (zh) 2017-02-24
CN113943366B (zh) 2024-12-13
NZ714320A (en) 2022-02-25
US11427628B2 (en) 2022-08-30
IL243311B (en) 2022-07-01
AU2014301629B2 (en) 2020-02-06
IL293477B2 (en) 2024-11-01
SG10201811017QA (en) 2019-01-30
JP2024026176A (ja) 2024-02-28
EP3013864A1 (en) 2016-05-04
KR102286053B1 (ko) 2021-08-04
AU2014301629A1 (en) 2015-12-10
CA2914829A1 (en) 2014-12-31
US10174102B2 (en) 2019-01-08
IL243311A0 (en) 2016-03-31
WO2014206561A8 (en) 2016-02-18
US20190119359A1 (en) 2019-04-25
KR20220029763A (ko) 2022-03-08
JP2022028659A (ja) 2022-02-16
AU2020202770B2 (en) 2023-01-05
IL293477B1 (en) 2024-07-01
KR20240000622A (ko) 2024-01-02
JP2016523537A (ja) 2016-08-12
IL313351A (en) 2024-08-01
SG11201509899PA (en) 2016-01-28
AU2020202770A1 (en) 2020-05-14
US20160130326A1 (en) 2016-05-12
US20230212265A1 (en) 2023-07-06
KR20160024923A (ko) 2016-03-07
KR20210097829A (ko) 2021-08-09
IL293477A (en) 2022-08-01
WO2014206561A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
JP6708544B2 (ja) 新規抗体フレームワーク
JP2016523537A5 (enExample)
JP2023115024A (ja) 新規の安定した抗体の可変領域フレームワークの組み合わせ
AU2012265156B2 (en) Dual targeting
US10738103B2 (en) Antibody light chains
US11365240B2 (en) Anti-HSA antibodies
CN104981482A (zh) 双靶向作用
Ebrahimi et al. Nanobody as a New Generation of Functional Proteins: Nanobody as a new functional domains
HK1205145B (en) Improved antibody light chains

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200521

R150 Certificate of patent or registration of utility model

Ref document number: 6708544

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250